This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Abdollah Iravani, MD
Orlando, Fla

Roger M. Echols, MD
West Haven, Conn

Alan Tice, MD
Tacoma, Wash

Thomas Nolen, MD
Columbiana, Ala

Harry Gallis, MD
Durham, NC

Arch Intern Med. 1996;156(1):112-113.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The concerns expressed by Ditmanson and Apgar regarding the use of ciprofloxacin as a short-course, low-dose treatment for uncomplicated urinary tract infections in otherwise healthy women are well expressed and not unexpected. Nevertheless, their generalizations about the problem of antimicrobial resistance should be dispelled by examination of available data. Certain microorganisms such as S aureus and P aeruginosa have been associated with development of quinolone resistance in the United States, usually in the hospital setting. However, there has been no significant development of resistance to the fluoroquinolones among the Enterobacteriaceae.¹ The issue of "inappropriate use" and, in particular, the anecdotal cases of treatment failures associated with S pneumoniae are not related to development of drug resistance. In fact, while the increasing resistance of S pneumoniae to penicillin is of great concern, there has been no change in the susceptibility of this organism to the quinolones, despite the significant use . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?